Print

Daniel A. Spyker Joins Alexza Molecular Delivery Corporation (MDC) As Vice President, Clinical & Regulatory Affairs 
10/19/2005 5:12:31 PM

PALO ALTO, Calif., Dec. 21 /PRNewswire/ -- Alexza Molecular Delivery Corporation ("Alexza") announced today that Daniel A. Spyker, M.D., Ph.D., has joined the company as Vice President, Clinical & Regulatory Affairs. Dr. Spyker was previously Director, Pharmacokinetics & Pharmacodynamic Sciences at Genentech and Senior Medical Director for Purdue Pharma. Before joining industry in 1999, Dr. Spyker was at the U.S. Food and Drug Administration (FDA), serving as Deputy Director for the Division of Cardiovascular, Respiratory & Neurological Devices 1994-1999 and Medical Officer, Pilot Drug Evaluation Staff in the Center for Drug Evaluation and Research from 1990-1994. He previously held positions as Assistant and Associate Professor of Internal Medicine at the University of Virginia School of Medicine. He is currently Adjunct Professor of Clinical Pharmacology at the Uniformed Services University of the Health Sciences. Dr. Spyker holds an M.D. from University of Virginia School of Medicine and a Ph.D. in Electrical Engineering and Mathematics from the University of Minnesota.

"I am very pleased to welcome Dan to our Alexza management team," said Thomas B. King, President and CEO. "Dan brings a broad and unique background of clinical and regulatory affairs experience, with his work in industry, in academia and with his tenure at the FDA. With multiple product candidates planned for clinical development in 2005, Dan's expertise integrated with our strong team of scientists and engineers, make this a very exciting time for Alexza."

Alexza was co-founded by biotechnology and drug delivery pioneer, Dr. Alejandro Zaffaroni. Alexza is developing proprietary products using the company's core platform, Staccato(TM) technology. This Staccato technology enables the rapid onset of therapeutic effect of many small molecule drugs as well as patient self-titration to the lowest effective dose to better treat acute and intermittent conditions. Alexza has one product candidate in early clinical development and three additional product candidates in preclinical development.

Alexza Molecular Delivery Corporation

CONTACT: Thomas B. King, President & CEO of Alexza Molecular DeliveryCorporation, +1-650-687-3902


//-->